Rủi ro tim mạch trong viêm khớp dạng thấp và các rối loạn tự miễn dịch hệ thống: một mô hình chiến lược phòng ngừa được đề xuất

Holmqvist ME, Wedrén S, Jacobsson LTH et al (2010) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis among patients diagnosed between 1995 and 2006. J Intern Med 268:578–585 Shoenfeld Y, Gerli R, Doria A et al (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112:3337–3347 Nurmohamed MT (2009) Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 8:663–667 Bartoloni Bocci E, Luccioli F, Angrisani C, Moscatelli S, Alunno A, Gerli R (2007) Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diseases. Expert Rev Clin Immunol 3:531–541 Sarzi-Puttini P, Azteni F, Gerli R et al (2010) Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 9:849–852 Gerli R, Vaudo G, Bocci EB et al (2010) Functional impairment of arterial wall in primary Sjögren’s syndrome: combined action of immunological and inflammatory factors. Arthritis Care Res 62:712–718 Vaudo G, Bocci EB, Shoenfeld Y et al (2005) Precocious intima-media thickening in patients with primary Sjögren’s syndrome. Arthritis Rheum 52:3890–3897 Bartoloni E, Shoenfeld Y, Gerli R (2010) Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res. doi:10.1002/acr.20322 Bartoloni E, Alunno A, Luccioli F et al (2010) Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link. Expert Rev Cardiovasc Ther 8:1309–1316 Bartoloni E, Alunno A, Bistoni O, Gerli R (2010) How early is the atherosclerotic risk in rheumatoid arthritis? Autoimmun Rev 9:701–707 Holmqvist ME, Wedrèn S, Jacobsson LT et al (2010) No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis. Results from two Swedish population-based rheumatoid arthritis cohorts. Arthritis Rheum 60:2861–2869 Gabriel SE, Crowson CS, Kremers HM et al (2003) Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48:54–58 Solomon DH, Goodson NJ, Katz JN et al (2006) Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 65:1608–1612 Peters MJ, Symmons DP, McCarey D et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69:325–331 Toms TE, Panoulas VF, Douglas KM et al (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis 69:683–688 Metsios G, Stavropoulos-Kalinoglou A, Sandoo A et al (2010) Vascular function and inflammation in rheumatoid arthritis: the role of physical activity. Cardiovasc Med J 4:89–96 Libby P, Okamoto Y, Rocha V, Folco E (2010) Inflammation in atherosclerosis: transition from theory to practice. Circ J 74:213–220 Turesson C, Matteson EL (2007) Cardiovascular risk factors, fitness and physical activity in rheumatic diseases. Curr Opin Rheumatol 19:190–196 Volkmann ER, Grossman JM, Sahakian LJ et al (2010) Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res 62:258–265 McMahon M, Grossman I, Skaggs B et al (2009) Dysfunctional proinflammatory high density lipoproteins confer increased risk for atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 60:2428–2437 Steiner G, Urowitz M (2009) Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Arthritis Rheum 38:372–381 Gerli R, Bocci EB, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y (2006) Traditional cardiovascular risk factors in primary Sjögren’syndrome: role of dyslipidemia [letter]. Rheumatology 45:1580–1581 Abeles AM, Pillinger MH (2006) Statins are anti-inflammatory and immunomodulatory agents: a future in rheumatologic therapy. Arthritis Rheum 54:393–407 Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6:1833–1846 Bisoendial RJ, Stroes ES, Kastelein JJ, Tak PP (2010) Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol 6:157–164 Jick SS, Choi H, Li L, McInnes IB, Sattar N (2009) Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 68:546–551 Paraskevas KI (2008) Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27:281–287 McCarey D, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021 Lodi S, Evans SJ, Egger P, Carpenter J (2010) Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 69:85–94 Petri M, Kiani AN, Post W et al (2006) Lupus Atherosclerosis Prevention Study (LAPS): randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 54:S520 Choy E, Sattar N (2009) Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 68:460–469 Dixon WG, Watson KD, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912 Pérez-De-Lis M, Akasbi M, Sisó A et al (2010) Cardiovascular risk factors in primary Sjögren’s syndrome: a case–control study in 624 patients. Lupus 19:941–948 Kitas G, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8–14 Panoulas VF, Douglas KM, Smith JP et al (2009) Transforming growth factor-beta1 869T/C, but not interleukin-6-174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology 48:113–118 Panoulas VF, Toms TE, Metsios GS et al (2010) Target organ damage in patients with rheumatoid arthritis: the role of blood pressure and heart rate. Atherosclerosis 209:255–260 Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN (2010) Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: a Greek Cohort Study. J Rheumatol. doi:10.3899/jrheum.100564 Danowski A, Leitão N, de Azevedo M, de Souza Papi JA, Petri M (2009) Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 36:1195–1199 Flammer AJ, Sudano I, Hermann F et al (2008) Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 117:2262–2269 Perry ME, Chee MM, Ferrell WR, Lockhart JC, Sturrock RD (2008) Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis. Ann Rheum Dis 67:1646–1647 Durán-Barragán S, McGwin G Jr, Vilá LM, Reveille JD, Alarcón GS (2008) Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus—results from LUMINA (LIX): a multiethnic US cohort. Rheumatology 47:1093–1096 Bussone G, Bérezné A, Pestre V, Guillevin L, Mouthon L (2010) The scleroderma kidney: progress in risk factors, therapy, and prevention. Curr Rheumatol Rep. doi:10.1007/s11926-010-0145-7 van Halm VP, Peters MJ, Voskuyl AE et al (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. Ann Rheum Dis 68:1395–1400 Parker B, Bruce IN (2010) The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am 36:81–97 Sabio JM, Vargas-Hito J, Zamora-Pasadas M et al (2009) Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36:2204–2211 Shahin D, Eltoraby E, Mesbah A, Houssein M (2010) Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 43:661–665 Chung CP, Oeser A, Solus JF et al (2008) Inflammation associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58:2105–2112 Venegas-Pont M, Sartori-Valinotti JC, Maric C et al (2009) Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296:R1282–R1289 Zhao W, Thacker SG, Hodgin JB (2009) The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol 183:2729–2740 Kaprove Penn S, Kao AH, Schott LL et al (2010) Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 37:1136–1142 Morris SJ, Wasko MC, Antohe JL et al (2010) Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Rheum. doi:10.1002/acr.20393 Jung H, Bobba R, Su J et al (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62:863–868 Turesson C, Jacobsson LT, Matteson E (2008) Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 4:605–614 del Rincon I, O’Leary DH, Haas RW et al (2004) Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 50:3813–3822 Westlake SL, Colebatch AN, Baird J (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 49:295–307 Hochberg MC, Johnston SS, John AK (2008) The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 24:469–480 Ristic G, Lepic T, Glisic B et al (2010) Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. Rheumatology 49:1076–1081 Georgiadis AN, Voulgari PV, Argyropoulou MI et al (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38:13–19 Angel K, Aarrestad Provan S, Lovahl Gulseth H, Mowinckel P, Kvien K, Atar D (2010) Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies. A controlled study. Hypertension 55:333.38 Kerekes G, Soltsèz P, Dèr H et al (2009) Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 1173:814–821 Gallaraga B, Belch JJ, Pullar T, Ogston S, Khan F (2010) Clinical improvement in rheumatoid arthritis is associated with healthier microvascualr function in patients who respond to antirheumatic therapy. J Rheumatol 37:521–528 Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J (2010) Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-alpha therapy. Ann N Y Acad Sci 1193:153–159 Gerli R, Schillaci G, Giordano A et al (2004) CD4+CD28null T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109:2744–2748 Gerli R, Vaudo G, Bartoloni Bocci E, Schillaci G, Bistoni O, Shoenfeld Y (2009) Different roles for anti-cyclic citrullinated peptide antibodies and CD4+CD28null cells in the acceleration of atherosclerosis in rheumatoid arthritis: comment on the article by Farragher et al. Arthritis Rheum 60:631–632 Gerli R, Bocci EB, Shoenfeld Y (2006) Effect of tumor necrosis factor α inhibition on CD28 surface expression on CD4+ T cells. Arthritis Rheum 54:3060–3061 Kerekes G, Soltsez P, Der H et al (2009) Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis and lipid profile in rheumatoid arthritis. Clin Rheumatol 28:705–710 Bruce IN (2005) Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 19:823–838